Se
Sensei Bio
S San Francisco CAFounded 202040 employees
Private CapbiotechPrivateOncology
Platform: SNS-301 HLADR
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Datotuximab | SEN-9870 | Phase 1/2 | 1 | TROP-2 | SCLCAS | ||
| SEN-3594 | SEN-3594 | Phase 2/3 | 2 | LAG-3 | CMLCTCL | ||
| Elratuximab | SEN-4317 | Phase 1 | 1 | FGFR | GIST | ||
| SEN-1840 | SEN-1840 | Phase 2 | 2 | BET | Rett |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)